The association of baseline adipocytokine levels with glycemic progression in nondiabetic Korean adults in 4 years of follow-up.
OBJECTIVE
Low-grade inflammation and lipotoxicity contribute to insulin resistance and islet secretory dysfunction that lead to insulin deficiency. We analyzed the associations of several adipocytokines measured at baseline with glycemic progression in non-diabetic Korean subjects after a 4-year follow-up.


METHODS
In 479 non-diabetic Korean subjects who underwent medical screening in 2003, serum tumor necrosis factor (TNF)-α, interleukin (IL)-6, retinol-binding protein (RBP)-4, monocyte chemoattractant protein (MCP)-1, visfatin and fatty acid-binding protein (FABP)-4 were measured at baseline. After 4 years, changes in glycemia were assessed.


RESULTS
Among the subjects, 79.2% maintained their baseline glycemic status, 14.6% progressed to worse glycemic status (impaired fasting glucose (IFG) to diabetes, normoglycemia to IFG or normoglycemia to diabetes) and 5.8% regressed to normoglycemia after 4 years. Baseline TNF-α and FABP4 showed the highest values in the progression group. In the logistic regression analyses with glycemic progression as the dependent variable and TNF-α and FABP4 as independent variables in separate models, TNF-α and FABP4 individually predicted glycemic progression after adjustment for confounding variables. When both adipocytokines were included in the same model, only FABP4 significantly predicted glycemic progression after 4 years.


CONCLUSIONS
TNF-α and FABP4 were significant predictors for glycemic progression in 4 years, with FABP4 being the stronger predictor.
Department of Endocrinology and Metabolism, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Eun-Jung
EJ
Rhee
Mi Hae
MH
Seo
Won Seon
WS
Jeon
Hee Kwan
HK
Won
Ji-Hun
JH
Choi
Se Eun
SE
Park
Cheol-Young
CY
Park
Hyon Joo
HJ
Kwag
Ki-Won
KW
Oh
Sung-Woo
SW
Park
Sun-Woo
SW
Kim
Won-Young
WY
Lee
D054392:Adipokines / Q000097:blood*; D000328:Adult; D015415:Biomarkers / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000453:epidemiology / Q000276:immunology / Q000503:physiopathology; D018450:Disease Progression; D050556:Fatty Acid-Binding Proteins / Q000097:blood*; D005260:Female; D005500:Follow-Up Studies; D018149:Glucose Intolerance / Q000097:blood / Q000453:epidemiology / Q000276:immunology / Q000503:physiopathology; D044882:Glucose Metabolism Disorders / Q000097:blood* / Q000453:epidemiology / Q000276:immunology / Q000503:physiopathology*; D006801:Humans; D016015:Logistic Models; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D011236:Prediabetic State / Q000097:blood / Q000453:epidemiology / Q000276:immunology / Q000503:physiopathology; D011446:Prospective Studies; D056910:Republic of Korea / Q000453:epidemiology; D012306:Risk; D014409:Tumor Necrosis Factor-alpha / Q000097:blood*
D054392:Adipokines; D015415:Biomarkers; C493410:FABP4 protein, human; D050556:Fatty Acid-Binding Proteins; D014409:Tumor Necrosis Factor-alpha